South Australian Gastroenterpancreatic (GEP) Neuroendocrine Cancer Care Pathway

The Unicorn Foundation was very excited to see the launch of the South Australian Cancer Care Pathway for Gastroenteropancreatic neuroendocrine cancers (GEP-NETs) at this years COSA Annual Scientific Meeting by the South Australian Minister for Health and Ageing, Hon Jack Snelling MP.

The initiative for the development occurred during a meeting of Prof Dorothy Keefe and Dr John Leyden in Adelaide in 2012 and a commitment was made by the Unicorn Foundation to support a research nurse to lead the project. Koli Ali performed this task with enthusiasm, dedication and lots of hard work. The GEP NET Working Party was made up of South Australia's most experienced physicians, surgeons and allied health staff in the field of neuroendocrine cancers.

To view this pathway follow the link – SA GEP NET Cancer Care Pathway

The Unicorn Foundation is very proud to have been involved in this project and believe it to be a very important pathway that will improve the medical management and quality of life of all South Australian NET patients.

We would also like to thank the fantastic work of the NET Nurses in SA who manned our booth at COSA, and raised much needed awareness and money from their fantastic sales from Unicorn Foundation merchandise.

The development of this pathway would not have happened without the generous donations made to the Unicorn Foundation from our many supporters. Thank you. 
 

Share this article

Subscribe to our Newsletter

Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.

Related News

Australia delivers excellent cancer care, but not equally

NECA Christmas and New Year Closure Details

Announcing our First Patient Ambassador – Cassie Miller

NET Patient Chris, from Ballarat, Raises Awareness of Neuroendocrine Cancer

Walk, run, or ride this March4NETs!

For its third year, March4NETs will run throughout March 2026.

Get involved and support the 31,000 Australians living with neuroendocrine cancer.